Asciminib (Scemblix)

Asciminib at a glance

Asciminib is available under the verified brand Scemblix. It blocks a protein called BCR::ABL1, which helps certain abnormal blood cells grow. The team uses your diagnosis and laboratory findings to decide whether this target is relevant.

The tablets are taken on an empty stomach. The prescribed schedule may be once or twice daily, and the dose can differ substantially when a particular change called T315I is present. Do not copy another person's tablet count or change between schedules yourself.

Regular blood tests check blood cells and pancreatic enzymes. Blood pressure and heart-related risks also need attention. Common difficulties include tiredness, muscle or joint pain, headache, rash and bowel changes. Serious problems can occur even though this is a targeted treatment.

Keep an up-to-date medicine list and the hospital's urgent contact details with you. A record of the dose, tablet strength, meal times and any symptoms can make appointments more useful. There is no need to remember every medical term in this guide; the important things are following your own plan and recognising when to seek help.

How asciminib works

BCR::ABL1 is an abnormal protein formed when genetic material is rearranged. The associated chromosome change is often called the Philadelphia chromosome. The protein sends signals that encourage affected cells to multiply. Asciminib interferes with this process by attaching to a specific part of the protein, called its myristoyl pocket.

It belongs to the tyrosine kinase inhibitor, or TKI, group. Its attachment site differs from that used by several other BCR::ABL1 inhibitors. This does not mean it is automatically the best option for everyone or that another TKI's instructions apply to it.

Treatment response is assessed with laboratory results and clinical review. Feeling better is welcome, but it cannot replace these checks. Equally, having few side effects does not mean treatment has stopped working. Your team can explain the response they hope to see and how they will interpret changes over time.

How your team decides whether it is suitable

The assessment considers the precise diagnosis, disease phase, BCR::ABL1 findings, previous medicines, any resistance mutations and your overall health. T315I testing can matter because the recommended asciminib dose is different when this mutation is relevant. Testing and dose selection belong together; a dose difference is not simply a measure of how unwell someone feels.

Tell your team about previous pancreatitis, heart disease, stroke, circulation problems, blood clots, high blood pressure, hepatitis B, liver or kidney disease. Mention any previous reaction to a cancer medicine and any difficulty swallowing tablets. These details may affect the choice of treatment or the monitoring plan.

Ask what treatment is intended to achieve, how often response will be measured and what would lead to a change. If arranging fasting periods around work or meals looks difficult, raise this before starting. A workable daily routine is part of safe treatment, rather than an issue you must solve alone.

Before treatment starts

Baseline checks usually include blood counts and tests relevant to the liver, kidneys and pancreas, alongside blood pressure and a medicine review. Pregnancy status is checked when applicable. The European prescribing information recommends a heart tracing, or ECG, before treatment and correction of low potassium or magnesium. Follow-up heart checks depend on clinical need.

The European information also advises hepatitis B testing before treatment. This precaution reflects reactivation reported with other BCR::ABL1 inhibitors. A previous infection does not automatically prevent treatment, but the team may arrange specialist advice, preventive treatment or additional monitoring.

Bring all prescribed and non-prescribed products to the medicine review, including supplements, herbal preparations and medicines taken only occasionally. Check that you understand the tablet strength, number per dose, daily schedule and fasting window. Ask which symptoms require the urgent line and where to go if you cannot reach the team promptly.

How to take asciminib

Your dose and schedule

Common label schedules are 80 mg once daily or 40 mg twice daily. When the relevant T315I mutation is present, the recommended schedule is 200 mg twice daily. A clinician may prescribe a reduced dose because of side effects. These examples explain why prescriptions differ; they are not instructions to select your own dose.

The European information notes that the two schedules have not been formally shown to work equally well in all situations, and that twice-daily treatment may offer an advantage for some previously treated patients. Your specialist chooses the schedule using your treatment history; convenience alone should not determine a switch.

For twice-daily treatment, doses are usually about 12 hours apart. For once-daily treatment, use approximately the same time each day. Current reviewed labels include 20 mg, 40 mg and 100 mg tablets. The European information restricts use of the 100 mg strength to the T315I setting. Check the strength at each supply and follow the written tablet count.

Food and swallowing

Avoid food for at least two hours before each dose and at least one hour afterwards. Swallow the tablets whole with water. For example, a dose at 8 am requires no food after 6 am and no breakfast before 9 am; an evening schedule needs its own fasting window. Your pharmacist can help plan this around your normal meals.

Do not crush, chew or break the tablets. If swallowing is difficult or a feeding tube is needed, contact the team before the next dose for a specific plan. Do not improvise a mixture or use another medicine's dispersion instructions. Tell the pharmacist about relevant lactose intolerance or an ingredient allergy.

A missed dose or vomiting

For once-daily treatment, skip a dose that is more than about 12 hours late. For twice-daily treatment, skip one that is more than about six hours late. If you remember earlier, take it while respecting the fasting instructions, then continue as directed. Never double a dose. If you are uncertain near the time limit or cannot fit the food window, contact your pharmacist.

If you vomit after taking asciminib, do not take an extra dose; take the next dose at the usual time. Report repeated vomiting or difficulty keeping fluids down. An anti-sickness plan may need adjustment, and the team needs to know if doses are regularly being lost.

Storage and handling

Keep tablets in the original packaging, protected from moisture and out of children's reach. The US label specifies storage at 20–25°C (68–77°F), with permitted brief temperature excursions; follow your supplied pack's instructions. Avoid hot cars and damp bathrooms. Ask the pharmacist before transferring tablets into a different container. Return unused medicine through the hospital or pharmacy.

Monitoring and checking whether treatment is working

Blood counts are checked every two weeks for the first three months and then monthly or as clinically needed under the US schedule. The tests measure infection-fighting white cells, oxygen-carrying red cells and platelets, which help stop bleeding. Results may prompt a delay or a prescribed dose reduction before you notice symptoms.

Amylase and lipase are enzymes associated with the pancreas. The prescribing information calls for monthly checks or testing as needed; people with previous pancreatitis may need closer monitoring. A high enzyme result is not the same as a confirmed diagnosis of pancreatitis, but it needs interpretation, especially if abdominal symptoms occur.

Blood pressure, symptoms and cardiovascular risk factors are reviewed regularly. Additional tests may include liver chemistry, kidney function, salts and blood fats. The exact combination and frequency depend on your results and medical history. Ask for a written schedule rather than assuming every blood test is being performed at each visit.

Response testing is separate from safety monitoring. Your specialist follows BCR::ABL1 measurements and other findings to assess how well treatment is controlling the disease. Ask what your current result means compared with earlier results. Do not stop tablets because one result has improved or because you feel well.

Common side effects and practical care

Tiredness and reduced stamina

Fatigue may affect concentration, housework and employment as well as physical activity. Plan demanding tasks for times when you feel better, accept practical help and balance rest with manageable activity. Report a marked change, particularly with breathlessness, dizziness or fever, because anaemia, infection or another problem may need treatment.

Muscle and joint discomfort

Describe where the pain is, when it began and whether it limits walking or sleep. Gentle movement and comfortable positioning may help, but persistent pain deserves review. Check before starting regular painkillers: some may be unsuitable when platelets are low or because of other medicines. New severe weakness or dark urine needs prompt assessment.

Nausea and bowel changes

Use prescribed anti-sickness or diarrhoea medicines as directed. Small drinks and meals outside the fasting windows may be easier to manage. Keep track of loose stools compared with your usual pattern. Report persistent diarrhoea, inability to drink, dizziness or reduced urine; fever, blood in the stool or severe abdominal pain needs urgent advice.

Constipation can also occur. Discuss it early, especially if other medicines contribute. Fluid, food and activity advice should fit your health and any fluid restriction. Do not keep escalating laxatives yourself if constipation comes with vomiting, a swollen abdomen or significant pain.

Rash, headaches and swelling

Report a new or worsening rash. Gentle skin care and an unperfumed moisturiser may help dry skin, but extensive rash or blistering needs assessment. Facial or throat swelling with breathing difficulty is an emergency. Headaches can occur, but a severe or unusual headache should not be dismissed as routine, particularly with vision change, confusion or high blood pressure.

Tell the team about ankle swelling, rapidly increasing swelling or weight change. New breathlessness needs prompt review rather than simply reducing activity. Symptoms may have several possible causes, and the team may need an examination or tests to distinguish them.

Less common but important side effects

Low blood counts, infection and bleeding

Asciminib can reduce blood-cell production. A low neutrophil count raises infection risk; low platelets increase bruising or bleeding; anaemia may cause pallor, tiredness or breathlessness. Contact the hospital promptly for infection symptoms, unexpected bruising, nosebleeds that persist, or blood in urine or stools. Heavy bleeding or collapse requires emergency care.

Pancreatitis

Inflammation of the pancreas can cause persistent upper abdominal pain, sometimes spreading to the back, with nausea or vomiting. Get urgent advice rather than treating this as ordinary indigestion. Severe pain or marked illness requires emergency assessment. Blood tests and sometimes imaging help establish the cause; the team may interrupt or stop asciminib depending on the findings.

Blood pressure, heart and circulation problems

Blood pressure can rise without obvious symptoms, which is why measurements matter. If home monitoring is advised, ask how to use the device and what readings require a call. Continue prescribed blood-pressure treatment unless your clinician changes it. Do not start aspirin or another preventive medicine on your own.

Serious heart and blood-vessel problems, including reduced blood supply and heart failure, have been reported. Seek emergency care for chest pressure, sudden severe breathlessness, collapse, new one-sided weakness or difficulty speaking. A painful, suddenly cold limb also needs emergency assessment. Palpitations, new swelling or breathlessness that is less severe still warrants prompt contact.

Asciminib can affect the heart's electrical rhythm, including prolonging a measurement called QT. The risk assessment includes other medicines and blood salts. Tell the team about fainting or a racing or irregular heartbeat. Do not take potassium or magnesium supplements to correct a suspected problem without test-based advice.

Allergy, liver changes and viral reactivation

An allergic reaction may cause rash, swelling, wheezing or faintness. Stop taking the medicine and get immediate medical help for signs of a serious reaction; breathing or swallowing difficulty requires emergency services. Do not restart after a suspected serious allergy until assessed.

Liver blood tests may change. Report yellow eyes or skin, dark urine, pale stools or persistent right-sided abdominal discomfort. If you previously had hepatitis B, follow the monitoring plan during treatment and for the advised period afterwards. Do not assume a remote infection is irrelevant because it caused no recent symptoms.

Other medicines, supplements and vaccinations

Asciminib can both affect other medicines and be affected by them. Interactions may be more important at the 200 mg twice-daily dose. Ask for a pharmacist check whenever a medicine is started, stopped or changed, including antibiotics, antifungals, seizure medicines, anticoagulants and heart medicines.

Examples needing careful assessment include warfarin, digoxin and certain statins. Current US information advises close monitoring with rosuvastatin and dose adjustment according to its own prescribing information when necessary. Do not stop a heart-protective medicine yourself. The itraconazole oral solution containing hydroxypropyl-beta-cyclodextrin has a specific interaction and should be avoided with asciminib; the formulation matters.

Warfarin needs particular attention. US information recommends avoiding certain combinations that increase its exposure; if an alternative cannot be used, your specialist must decide the safest plan. European information calls for more frequent INR blood tests when warfarin cannot be avoided at the higher asciminib dose. Do not stop an anticoagulant abruptly or adjust it yourself.

St John's wort and other herbal or traditional preparations also need review. Give the pharmacist the actual ingredients rather than only describing a product as natural. Avoid assuming that spacing two interacting medicines by a few hours removes the interaction.

Discuss vaccinations with the haematology team. Live vaccines may be unsuitable while immunity is reduced; the choice and timing depend on blood counts, treatment and the vaccine. Non-live vaccines may still be recommended. Check travel vaccinations before booking a trip, and tell vaccination staff that you take asciminib.

Everyday life during treatment

Plan food around the fasting windows without unnecessarily restricting the rest of your diet. If weight loss, nausea or another condition makes this difficult, request dietitian or pharmacy support. Drink an amount appropriate for your health; people with heart or kidney conditions may have individual limits.

Wash hands regularly, practise food safety and avoid close contact with people who are acutely unwell, particularly when blood counts are low. Report mouth sores, painful urination or an infected-looking wound. Infection precautions should be tailored to your risk; ask the team what this means for work, visitors and social activities.

You may be able to continue work with adjustments to hours, appointments or physically demanding duties. Avoid driving or machinery while dizzy, unusually tired or otherwise impaired. Discuss planned dental work and operations with both teams so that blood counts, infection risk and medicine interactions can be considered.

Before travel, arrange enough tablets, safe storage, a time-zone dosing plan and access to urgent care. Keep medicines in labelled original packaging. Do not omit monitoring visits to accommodate travel without discussing an alternative. If worry about test results or long-term treatment affects sleep or relationships, tell the team; psychological and practical support can be part of care.

Fertility, contraception, pregnancy and breastfeeding

Asciminib can harm a developing baby. Pregnancy testing is recommended before treatment when relevant. Effective contraception is needed during treatment, with a specified period after the final dose. US information gives one week for female patients who can become pregnant; European information gives at least three days. Follow the written plan for your prescribed product and any longer interval required by accompanying treatment.

Do not breastfeed during treatment. The US restriction continues for one week after the last dose; the European restriction is at least three days. Agree a safe feeding plan with your team rather than choosing the shorter period yourself. Contact the team promptly if pregnancy occurs or is suspected.

The effects on human fertility are uncertain. Animal findings prompt concern, and the US label warns about possible impairment of female fertility. Discuss future parenthood and preservation options before treatment if relevant. The reviewed labels do not provide a matching universal post-treatment contraception interval for male patients; obtain individual advice rather than borrowing the female interval or another TKI's rule.

After treatment finishes

Stopping asciminib should be a planned specialist decision. A good response does not mean you can stop without monitoring, and a temporary interruption for toxicity is different from ending treatment permanently. Ask who will tell you when to restart and at what dose. Keep the most recent instruction in writing.

After the final dose, continue the agreed blood tests, symptom reporting and response assessments. If hepatitis B monitoring applies, it may continue for months. Maintain contraception and breastfeeding restrictions for the prescribed interval. Return unused tablets and tell other clinicians when treatment ended, especially if other medicines were adjusted because of interactions.

Frequently asked questions